| 臺大學術典藏 |
2020-04-10T12:16:12Z |
Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapy
|
YU-YUN SHAO; Lu L.-C.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:16:12Z |
Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma
|
YU-YUN SHAO; Chen P.-J.; Lin Z.-Z.; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:11Z |
Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma
|
Shau W.-Y.; YU-YUN SHAO; Yeh Y.-C.; Lin Z.-Z.; Kuo R.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:10Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
YU-YUN SHAO; Lu L.-C.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:10Z |
Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinoma
|
Cheng A.-L.; YU-YUN SHAO; Chen C.-L.; Ho M.-C.; Huang C.-C.; Tu H.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:16:10Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
Yeh K.-H.; Cheng A.-L.; Lin Y.-L.; Hsu C.; Cheng W.-F.; Hsu C.-H.; YU-YUN SHAO; Lu L.-C. |
| 臺大學術典藏 |
2020-04-10T12:16:10Z |
Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy
|
YU-YUN SHAO; Huang C.-C.; Lin S.-D.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:09Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.; Cheng A.-L.; Jin K.; Hsu C.-H.; Kang Y.K.; Yang T.-S.; Shun C.-T.; YU-YUN SHAO; Su W.-C.; Sandoval-Tan J.; Chiou T.-J. |
| 臺大學術典藏 |
2020-04-10T12:16:09Z |
Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma
|
Kuo R.N.C.; Lin Z.-Z.; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S.; Lu L.-C.; YU-YUN SHAO |
| 臺大學術典藏 |
2020-04-10T12:16:09Z |
The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma
|
Chang Y.-L.; YU-YUN SHAO; Huang C.-Y.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:08Z |
β-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.-H.; Lu L.-C.;Yu-Yun Shao;Lee Y.-H.;Hsieh M.-S.;Hsiao C.-H.;Lin H.-H.;Kao H.-F.;Ma Y.-Y.;Yen F.-C.;Cheng A.-L.;Hsu C.-H.; Lu L.-C.; YU-YUN SHAO; Lee Y.-H.; Hsieh M.-S.; Hsiao C.-H.; Lin H.-H.; Kao H.-F.; Ma Y.-Y.; Yen F.-C. |
| 臺大學術典藏 |
2020-04-10T12:16:08Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lin Z.-Z.; Shau W.-Y.; Hsu C.; YU-YUN SHAO; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:07Z |
Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy
|
Lu L.-C.;Yu-Yun Shao;Chan S.-Y.;Hsu C.-H.;Cheng A.-L.; Lu L.-C.; YU-YUN SHAO; Chan S.-Y.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:07Z |
Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases
|
Yu-Yun Shao;Ho M.-C.;Cheng A.-L.;Hsu C.-H.; YU-YUN SHAO; Ho M.-C.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:16:06Z |
Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
|
Yen F.-C.; Hsu C.-H.; Cheng A.-L.; YU-YUN SHAO; Wu C.-H.; Lu L.-C.; Chan S.-Y.; Ma Y.-Y.; Yu-Yun Shao;Wu C.-H.;Lu L.-C.;Chan S.-Y.;Ma Y.-Y.;Yen F.-C.;Hsu C.-H.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:03Z |
Integrated stable isotope labeling by amino acids in cell culture (SILAC) and isobaric tags for relative and absolute quantitation (iTRAQ) quantitative proteomic analysis identifies galectin-1 as a potential biomarker for predicting sorafenib resistance in liver cancer
|
Ho W.-C.; Tsai M.-H.; Feng W.-C.; Chow L.-P.; Hsu C.-H.; YU-YUN SHAO; Yeh C.-C.;Hsu C.-H.;Yu-Yun Shao;Ho W.-C.;Tsai M.-H.;Feng W.-C.;Chow L.-P.; Yeh C.-C. |
| 臺大學術典藏 |
2020-04-10T12:16:03Z |
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials
|
Chan S.-Y.; Shau W.-Y.; YU-YUN SHAO; Yu-Yun Shao;Shau W.-Y.;Chan S.-Y.;Lu L.-C.;Hsu C.-H.;Cheng A.-L.; Lu L.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:02Z |
Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?
|
Yu-Yun Shao;Hsu C.-H.;Cheng A.-L.; YU-YUN SHAO; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:02Z |
High serum transforming growth factor-β1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib
|
Lin T.-H.;Yu-Yun Shao;Chan S.-Y.;Huang C.-Y.;Hsu C.-H.;Cheng A.-L.; Lin T.-H.; YU-YUN SHAO; Chan S.-Y.; Huang C.-Y.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:02Z |
Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan
|
Yeh Y.-C.; Lai C.-L.; Lin Z.-Z.; Cheng A.-L.; Lai M.-S.; Yu-Yun Shao;Hsu C.-H.;Yeh K.-H.;Chen H.-M.;Yeh Y.-C.;Lai C.-L.;Lin Z.-Z.;Cheng A.-L.;Lai M.-S.; YU-YUN SHAO; Hsu C.-H.; Yeh K.-H.; Chen H.-M. |
| 臺大學術典藏 |
2020-04-10T12:16:01Z |
Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma
|
YU-YUN SHAO; Liu T.-H.; Lee Y.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:01Z |
Key opioid prescription concerns in cancer patients: A nationwide study
|
Fu W.-M.; Chen H.-M.; Lee Y.-H.; Lai M.-S.; YU-YUN SHAO; Hsu C.-H.; Lin C.-P.; Lin C.-P.;Hsu C.-H.;Fu W.-M.;Chen H.-M.;Lee Y.-H.;Lai M.-S.;Yu-Yun Shao |
| 臺大學術典藏 |
2020-04-10T12:16:00Z |
Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma
|
Lin H.-H.; Feng W.-C.; Lu L.-C.; YU-YUN SHAO; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:00Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration
|
YU-YUN SHAO; Chen B.-B.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-10T12:15:59Z |
Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study
|
Yeh Y.-C.; Chen P.-J.; Lu L.-C.;Chen P.-J.;Yeh Y.-C.;Hsu C.-H.;Chen H.-M.;Lai M.-S.;Yu-Yun Shao;Cheng A.-L.; Lu L.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; YU-YUN SHAO; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:59Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Chen Y.-C.; Ohishi N.; O’Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Frenette C.; Lin Z.-Z.; YU-YUN SHAO; Wan P.; Ma J.; Lyashchenko S.K.; Gansukh B.; Pandit-Taskar N.; Ruan S.; Beylergil V.; O’Donoghue J.; Abou-Alfa G.K.;Yen C.-J.;Hsu C.-H.;O’Donoghue J.;Beylergil V.;Ruan S.;Pandit-Taskar N.;Gansukh B.;Lyashchenko S.K.;Ma J.;Wan P.;Yu-Yun Shao;Lin Z.-Z.;Frenette C.;O’Neil B.;Schwartz L.;Smith-Jones P.M.;Ohtomo T.;Tanaka T.;Morikawa H.;Maki Y.;Ohishi N.;Chen Y.-C.;Agajanov T.;Boisserie F.;Di Laurenzio L.;Lee R.;Larson S.M.;Cheng A.-L.;Carrasquilo J.A.; Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A. |
| 臺大學術典藏 |
2020-04-10T12:15:58Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Yu-Yun Shao;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Hsu C.; YU-YUN SHAO; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-10T12:15:58Z |
Right or left? Side selection for a totally implantable vascular access device: A randomised observational study
|
Lin W.-Y.;Lin C.-P.;Hsu C.-H.;Lee Y.-H.;Lin Y.-T.;Hsu M.-C.;Yu-Yun Shao; Lin W.-Y.; Lin C.-P.; Hsu C.-H.; Lee Y.-H.; Lin Y.-T.; Hsu M.-C.; YU-YUN SHAO |
| 臺大學術典藏 |
2020-04-10T12:15:57Z |
Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure
|
Liu T.-H.;Hsu C.-H.;Yu-Yun Shao; Liu T.-H.; Hsu C.-H.; YU-YUN SHAO |
| 臺大學術典藏 |
2020-04-10T12:15:57Z |
Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells
|
Yu-Yun Shao;Hsieh M.-S.;Wang H.-Y.;Li Y.-S.;Lin H.;Hsu H.-W.;Huang C.-Y.;Hsu C.-H.;Cheng A.-L.; YU-YUN SHAO; Hsieh M.-S.; Wang H.-Y.; Li Y.-S.; Lin H.; Hsu H.-W.; Huang C.-Y.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:56Z |
Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
|
Lu L.-C.;Lee Y.-H.;Chang C.-J.;Shun C.-T.;Fang C.-Y.;Yu-Yun Shao;Liu T.-H.;Cheng A.-L.;Hsu C.-H.; Lu L.-C.; Lee Y.-H.; Chang C.-J.; Shun C.-T.; Fang C.-Y.; YU-YUN SHAO; Liu T.-H.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:15:55Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.;Yu-Yun Shao;Lu L.-C.;Shen Y.-C.;Hsu C.;Lin Z.-Z.;Hsu C.-H.;Cheng A.-L.; Liu T.-H.; YU-YUN SHAO; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:54Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L.; Yen C.-J.; Chao Y.; Lu L.-C.; Hsu C.; YU-YUN SHAO; Lu L.-C.;Hsu C.;Yu-Yun Shao;Chao Y.;Yen C.-J.;Shih I.-L.;Hung Y.-P.;Chang C.-J.;Shen Y.-C.;Guo J.-C.;Liu T.-H.;Hsu C.-H.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:54Z |
Potent activity of composite cyclin dependent kinase inhibition against hepatocellular carcinoma
|
Yu-Yun Shao;Li Y.-S.;Hsu H.-W.;Lin H.;Wang H.-Y.;Wo R.R.;Cheng A.-L.;Hsu C.-H.; YU-YUN SHAO; Li Y.-S.; Hsu H.-W.; Lin H.; Wang H.-Y.; Wo R.R.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:15:54Z |
Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
|
Guo J.-C.;Lin C.-C.;Lin C.-Y.;Hsieh M.-S.;Kuo H.-Y.;Lien M.-Y.;Yu-Yun Shao;Huang T.-C.;Hsu C.-H.; Guo J.-C.; Lin C.-C.; Lin C.-Y.; Hsieh M.-S.; Kuo H.-Y.; Lien M.-Y.; YU-YUN SHAO; Huang T.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:15:53Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Yu-Yun Shao;Liu T.-H.;Hsu C.;Lu L.-C.;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.;Hsu C.-H.; YU-YUN SHAO; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-09T09:42:28Z |
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials
|
Shao, Y.-Y.; Shau, W.-Y.; Chan, S.-Y.; Lu, L.-C.; Hsu, C.-H.; Cheng, A.-L. |
| 臺大學術典藏 |
2020-04-09T09:39:09Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao, Y. Y.; Chen, B. B.; Ou, D. L.; Lin, Z. Z.; Hsu, C. H.; Wang, M. J.; Cheng, A. L.; Hsu, C. |
| 臺大學術典藏 |
2020-04-09T09:31:03Z |
Key opioid prescription concerns in cancer patients: A nationwide study
|
Shao, Y. Y.; Lin, C. P.; Hsu, C. H.; Fu, W. M.; Chen, H. M.; Lee, Y. H.; Lai, M. S. |
| 臺大學術典藏 |
2020-04-08T02:10:16Z |
Drug-loaded hyaluronic acid hydrogel as a sustained-release regimen with dual effects in early intervention of tendinopathy
|
Hsiao M.-Y.;Lin A.-C.;Liao W.-H.;Tyng-Guey Wang;Hsu C.-H.;Chen W.-S.;Lin F.-H.; Hsiao M.-Y.; Lin A.-C.; Liao W.-H.; TYNG-GUEY WANG; Hsu C.-H.; Chen W.-S.; Lin F.-H. |
| 臺大學術典藏 |
2020-04-08T01:10:30Z |
The association of acquired T790M mutation with clinical characteristics after resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma
|
Yu, S.-L.; Yang, T.-Y.; Chang, G.-C.; Chang, G.-C.;Yang, T.-Y.;Yu, S.-L.;Chen, H.-W.;Chen, J.J.W.;Su, K.-Y.;Hsu, C.-H.;Chen, K.-C.;Tseng, J.-S.;Hsu, K.-H.;Huang, Y.-H.; Huang, Y.-H.; Hsu, K.-H.; Tseng, J.-S.; Chen, K.-C.; Hsu, C.-H.; Su, K.-Y.; Chen, J.J.W.; Chen, H.-W. |
| 臺大學術典藏 |
2020-04-07T13:17:43Z |
Drug-loaded hyaluronic acid hydrogel as a sustained-release regimen with dual effects in early intervention of tendinopathy
|
Hsiao M.-Y.; Lin A.-C.; Liao W.-H.; TYNG-GUEY WANG; Hsu C.-H.; Chen W.-S.; Lin F.-H. |
| 臺大學術典藏 |
2020-04-07T13:15:18Z |
The effect of the repression of oxidative stress on tenocyte differentiation: A preliminary study of a rat cell model using a novel differential tensile strain bioreactor
|
Liu L.; Lin F.-H.; Iafisco M.; Gefen A.; Wu Y.-W.; He C.-K.; Hsu C.-H.; Ming-Yen Hsiao;Lin P.-C.;Liao W.-H.;Chen W.-S.;Hsu C.-H.;He C.-K.;Wu Y.-W.;Gefen A.;Iafisco M.;Liu L.;Lin F.-H.; MING-YEN HSIAO; Lin P.-C.; Liao W.-H.; Chen W.-S. |
| 臺大學術典藏 |
2020-04-07T07:54:50Z |
Family-centered care improved neonatal medical and neurobehavioral outcomes in preterm infants: Randomized controlled trial
|
Yu Y.-T.; Hsieh W.-S.; Hsu C.-H.; Lin Y.-J.; Lin C.-H.; Hsieh S.; LU LU; Cherng R.-J.; Chang Y.-J.; Fan P.-C.; Yao N.-J.; Chen W.J.; Jeng S.-F. |
| 臺大學術典藏 |
2020-03-31T03:59:41Z |
Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non-randomized study
|
Hsu F.-M.;Lin C.-C.;Jang-Ming Lee;Chang Y.-L.;Hsu C.-H.;Tsai Y.-C.;Lee Y.-C.;Cheng J.C.-H.; Hsu F.-M.; Lin C.-C.; JANG-MING LEE; Chang Y.-L.; Hsu C.-H.; Tsai Y.-C.; Lee Y.-C.; Cheng J.C.-H. |
| 臺大學術典藏 |
2020-03-31T03:59:39Z |
Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensity-modulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomy
|
Cheng J.C.-H.; Tsai Y.-C.; Wu J.-K.; Lin C.-C.; Hsu C.-H.; JANG-MING LEE; Lee Y.-C.; Hsu F.-M. |
| 臺大學術典藏 |
2020-03-31T03:59:34Z |
Comparative study between endoscopic ultrasonography and positron emission tomography-computed tomography in staging patients with esophageal squamous cell carcinoma
|
Chang Y.-L.; Wang H.-P.; Hsu C.-H.; JANG-MING LEE; Cheng M.-F.; Yen R.-F.; Wu Y.-W.; Chung C.-S.; Yen T.-J. |
| 臺大學術典藏 |
2020-03-31T03:59:26Z |
Serum transforming growth factor-β1 change after neoadjuvant chemoradiation therapy is associated with postoperative pulmonary complications in esophageal cancer patients undergoing combined modality therapy
|
Hsu C.-H.; Koong A.C.; Chang D.T.; Chia-Hsien Cheng J.; Huang P.-M.; JANG-MING LEE; Tsai C.-L.; Wu J.-K.; Lu S.-L.; Hsu F.-M. |
| 臺大學術典藏 |
2020-03-31T03:59:26Z |
Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma
|
Wang C.-C.;Cheng J.C.-H.;Tsai C.-L.;Jang-Ming Lee;Huang P.-M.;Lin C.-C.;Hsu C.-H.;Hsieh M.-S.;Chang Y.-L.;Hsu F.-M.; Wang C.-C.; Cheng J.C.-H.; Tsai C.-L.; JANG-MING LEE; Huang P.-M.; Lin C.-C.; Hsu C.-H.; Hsieh M.-S.; Chang Y.-L.; Hsu F.-M. |
| 臺大學術典藏 |
2020-03-31T03:59:24Z |
Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma
|
Hsu C.-H.; Yeh K.-H.; Cheng A.-L.; Wang H.-P.; Cheng J.C.-H.; Hsu F.-M.; JANG-MING LEE; Huang P.-M.; Chang C.-H.; Lin C.-C.; Hsieh M.-S.; Guo J.-C.; Huang T.-C. |
